AirWare Labs Announces Additions to Executive Management Team

AirWare Labs Announces Additions to Executive Management Team 
Forward-Thinking Health Technology Solutions Company Strengthens
Resources; Poised for Tremendous Growth 
SCOTTSDALE, AZ -- (Marketwired) -- 02/19/14 --  AirWare Labs Corp.
(OTCQB: AIRW) today announced additions to its executive management
Dr. Lorrie Henderson, Ph.D., MBA has been appointed Chief Operating
Officer. In this role, Dr. Henderson will work to further the
business strategy and increase brand awareness, profitability and
shareholder value globally. Dr. Henderson brings over 25 years of
leadership experience in the field of Healthcare/Behavioral Health.
He earned his bachelor's degree from Florida Atlantic University, his
master's degree from Florida International University, a Ph.D. from
Barry University in Florida and an MBA, summa cum laude, from Jones
International University. 
Chase Herschman has been named the Director of Marketing. Herschman's
responsibilities include building brand and consumer awareness of the
AIR(R) line of products. A visionary in his own right, Herschman
joined AirWare Labs in 2013 after seeking to market his own nasal
filter product. He graduated from Indiana University with a degree in
Sports Marketing and Management in 2008. 
Michael L. Doll, Director of Quality, has been developing successful
products and business opportunities for over 30 years. Doll helped
developed the initial vision, definition and refinement of the
AirWare Labs nasal dilator and has been an integral part of the
organization since 2004. He graduated from University of Colorado
with a BS in Mechanical Engineering in 1985. 
Andy Shore, Director of Social Media, brings extensive social
networking and copywriting skill to AirWare Labs. Shore will focus on
delivering quality content to AirWare Labs' social media platforms to
increase engagement with and awareness of the AIR(R) brand and
product line. He graduated from Indiana University with a degree in
"Our new management team demonstrates AirWare Labs' commitment to
being an industry-leading organization," said Jeffrey Rassas,
President and CEO of AirWare Labs. "With these key additions we are
poised to build on the momentum we've created over the past year." 
AirWare Labs recently announced a licensi
ng agreement with Breathe
Active, LLC that includes a $2 million national television media
campaign. AIR(TM) ALLERGY was selected last month as a 2014 Visionary
Award Finalist for the VISION(R) Consumer Products Conference in
Dallas, and in 2013 AirWare Labs announced a national rollout into
7,500 Walgreen's stores. 
About AirWare Labs Corporation: 
AirWare Labs Corp., publicly traded as (OTCQB: AIRW), provides
patented and innovative technology solutions for consumer products
that promote better health through breathing and enhanced wellbeing.
AirWare Labs' products are marketed under the brand name of AIR(R).
AIR(R) products utilize an FDA approved medical grade silicone,
molded as an intranasal Air Breathe dilator, to act as the delivery
system. This AIR(R) microstructure enhances normal nasal airflow with
every breath -- clinically proven to deliver up to 40% more oxygen.  
Some AIR(R) products are infused with essential oils with unique
healing properties including antibacterial and therapeutic defense
against airborne allergens, viruses and bacteria. AIR(R) Allergy and
Travel products provide additional defense in the form of an
integrated filter media from 3M to remove microscopic particles that
carry viruses, allergens and bacteria. Other AIR(R) specialty
products help provide and performance enhancements and relief from
congestion, insomnia, headaches, nausea, and snoring. For more
product information, please visit: or
company information visit: 
Forward-Looking Statement: The statements in this press release
regarding any implied or perceived benefits from the release by
AirWare Labs Corp. of its AIR ALLERGY(TM) product are forward-looking
statements. Such statements involve risks and uncertainties,
including, but not limited to, risks and effects of legal and
administrative proceedings and governmental regulation, especially in
a foreign country, future financial and operational results,
competition, general economic conditions, and the ability to manage
and continue growth.  
Should one or more of these risks or uncertainties materialize, or
should underlying assumptions prove incorrect, actual outcomes may
vary materially from those indicated. Important factors that could
cause actual results to differ materially from the forward-looking
statements we make in this news release include the introduction of
new technology, market conditions and those set forth in reports or
documents we file from time to time with the SEC. We undertake no
obligation to revise or update such statements to reflect current
events or circumstances after the date hereof or to reflect the
occurrence of unanticipated events. 
Media Contact: 
Jennifer Breitegan 
Investor Relations:
Jeffrey Rassas
Press spacebar to pause and continue. Press esc to stop.